No Data
No Data
Cathie Wood's ARK Investment Buys 653K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc
Recursion Pharmaceuticals Analyst Ratings
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating
"Nvidia Magic" Strikes Again! Exploring Nvidia's Latest AI Investment Landscape